Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride

Next Previous
Trial Profile

A Phase 2a Multicenter, Randomized, Double-Blind, Parallel Group, 26-Week, Placebo-Controlled Study of SUVN-502 in Subjects With Moderate Alzheimer's Disease Currently Treated With Donepezil Hydrochloride and Memantine Hydrochloride

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Jun 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Masupirdine (Primary) ; Donepezil; Donepezil/memantine; Memantine
  • Indications Alzheimer's disease
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Suven Life Sciences

Most Recent Events

  • 01 Oct 2022 Results of post-hoc analysis assessing effects of masupirdine on the neuropsychiatric symptoms, published in the International Journal of Geriatric Psychiatry.
  • 04 Aug 2022 Results of post-hoc analysis assessing effect of masupirdine in patients with probable alzheimer's disease, presented at the Alzheimer's Association International Conference 2022.
  • 04 Aug 2022 Results of post hoc analysis assessing the impact of memantine on the efficacy of masupirdine by subdividing patients based on the use of memantine dosage form and memantine plasma concentrations, presented at the Alzheimer's Association International Conference 2022

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top